Healthcare Stocks Drive European Market Rally Amid Easing Debt Fears

European stock markets rallied on Tuesday, with the STOXX 600 benchmark climbing nearly 1% as healthcare stocks led the gains. The sector saw a 1.4% increase, the largest among European industry groups. Danish biotechnology company Genmab surged over 8%, reaching a three-year high after releasing promising late-stage clinical data for a lymphoma therapy developed in collaboration with AbbVie. The trial results showed a 51% reduction in the risk of disease progression or death for newly diagnosed patients with diffuse large B-cell lymphoma.

Beyond healthcare, other notable movers included Technoprobe, which gained after receiving an "overweight" rating from J.P. Morgan analysts, and Neinor Homes, which jumped more than 4% following upgraded financial projections. Meanwhile, bond yields in the eurozone pulled back after rising to multi-decade peaks last week due to concerns over France’s substantial debt obligations and legislative paralysis.

The euro remained near a 17-month low against the dollar, pressured by French debt worries and Spain’s unexpected election call. Market strategists suggested Spain might extend its existing budget framework to maintain debt on a downward trajectory without compromising immediate economic expansion. Additionally, expectations for further interest rate hikes from the European Central Bank have diminished, with traders now assigning an 80% probability to just one more hike before year-end.

Energy markets showed signs of stabilization, with crude oil prices steadying after an earlier drop. Telecom Plus also reported customer acquisition running above projections, lifting its shares by 4%. Attention is now turning to upcoming eurozone retail sales data and the third-quarter earnings reporting period.